Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.50 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 8/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887144 | 0.94 | PIK3CA (0.50) | PIK3CAMAP3K12MTORMAPTTSHR | |
| SCHEMBL3877301 | 0.92 | PIK3CA (0.48) | PIK3CAMAP3K12MTORMAPTTSHR | |
| SCHEMBL3879387 | 0.92 | PIK3CA (0.49) | PIK3CAMAP3K12MTORMALT1 | |
| SCHEMBL3884876 | 0.91 | MALT1 (0.44) | PIK3CAMALT1MAPTTSHRHSD17B10 | |
| SCHEMBL3876785 | 0.90 | GALR2 (0.43) | PIK3CAMALT1MAPTTSHRMAPK1 | |
| SCHEMBL3888444 | 0.90 | TRPV1 (0.49) | PIK3CAMAP3K12MTOR | |
| SCHEMBL3878644 | 0.90 | TRPV1 (0.49) | PIK3CAMAP3K12MTOR | |
| SCHEMBL4151864 | 0.89 | MTOR (0.46) | PIK3CAMAP3K12MTORMAPTTSHR | |
| SCHEMBL3879003 | 0.89 | MALT1 (0.46) | PIK3CAMAP3K12MTORMALT1 | |
| SCHEMBL13761243 | 0.89 | TRPV1 (0.47) | PIK3CAMTORMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | PIK3CA 1107/4885MAP3K12 2603/4885MTOR 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.